Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML
Author:
Affiliation:
1. 1Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan
2. 2Division of Clinical Laboratory, Okayama University Hospital, Okayama, Japan
3. 3Division of Blood Transfusion, Okayama University Hospital, Okayama, Japan
Publisher
American Society of Hematology
Subject
Hematology
Link
https://ashpublications.org/bloodadvances/article-pdf/7/5/681/2038507/blooda_adv-2022-008991r1-main.pdf
Reference11 articles.
1. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis;Brunet;J Clin Oncol,2012
2. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial;Perl;Blood,2022
3. Clinical outcomes in patients with FLT3-ITD-mutated relapsed/refractory acute myelogenous leukemia undergoing hematopoietic stem cell transplantation after quizartinib or salvage chemotherapy in the QuANTUM-R trial;Ganguly;Transplant Cell Ther,2021
4. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia;Maziarz;Bone Marrow Transplant,2021
5. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN);Burchert;J Clin Oncol,2020
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia;International Journal of Molecular Sciences;2024-08-30
2. FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AML;2024-08-26
3. How Could We Further Improve the Gilteritinib Maintenance After Allogeneic Hematopoietic Cell Transplantation in FLT3-Mutated AML?;Journal of Clinical Oncology;2024-07-31
4. Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2024-07
5. Post‐stem cell transplant maintenance in FLT3mut acute myeloid leukemia – A retrospective analysis: Outcomes are improved with midostaurin but not with gilteritinib;eJHaem;2024-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3